CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE NON-SMALL CELL LUNG CANCER OFFICIALLY INITIATED IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase III clinical study (Protocol No.: SYS6010–022 (SYNSTAR-04)) of SYS6010 in combination with enlonstobart for the treatment of driver-gene negative non-small cell lung cancer (the "**NSCLC**") developed by the Group officially initiated in China, with the enrolment of the first subject expected to be completed in July 2026.

SYS6010 is an antibody-drug conjugate ("**ADC**") targeting the epidermal growth factor receptor ("**EGFR**") developed by the Group. It is composed of a humanised anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker. This drug specifically binds to EGFR on the surface of tumour cells and releases the cytotoxic payload intracellularly upon internalisation, thereby exerting anti-tumour effects. Enlonstobart Injection (recombinant fully human anti-PD-1 monoclonal antibody injection) is a humanised IgG4 variant monoclonal antibody targeting programmed cell death protein 1 (PD-1), which is indicated for the treatment of malignant tumors in various human organs and tissues.

SYS6010–022 (SYNSTAR-04) is a randomised, open-label, multi-centre, Phase III clinical study designed to evaluate the efficacy and safety of SYS6010 in combination with enlonstobart versus immunotherapy plus platinum-based chemotherapy in subjects with driver gene-negative and programmed cell death ligand-1 (PD-L1)-positive locally advanced or metastatic NSCLC. Previously, the Group received the opinion from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China in May 2026, granting approval to conduct this clinical trial. Currently, the recruitment and screening of subjects are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 26 June 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.